Blog Reports
Check DailyStock reports by date and topic.
-
![[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September](https://daily-stock.kr/stdaily/uploads/202606/gen_6a2676d12d4578.84092915.png)
[KOSDAQ Story] HLB (028300) Clinical Trials & FDA Approval Timeline Amid Black Monday Crash: Critical Milestones for Liver Cancer in July and Cholangiocarcinoma in September
HLB faces major commercialization milestones with upcoming FDA decisions: the PDUFA target date for its liver cancer therapy on July 23, 2026, and a decision on its cholangiocarcinoma treatment expected by September 27.
-
![[S&P Insights] S&P 500 Healthcare's True Earnings Strength and Results Diagnosis Veiled by the Merck Illusion](https://daily-stock.kr/stdaily/uploads/202606/gen_6a26146df265d1.06288109.png)
[S&P Insights] S&P 500 Healthcare's True Earnings Strength and Results Diagnosis Veiled by the Merck Illusion
While the S&P 500 experiences volatility near record highs, the healthcare sector is emerging as a potential leader. Stripping away the temporary illusion from Q1 results, the sector's fundamental earnings power remains robust.
-
Nasdaq-100 ETF QQQ Resumes Inflows: Amid 4.5% Treasury Yield Pressure, What Will Global Investors and Retail Seohak Ants Choose?
Despite market volatility and rising US 10-year Treasury yields past 4.5%, Invesco QQQ has seen a major turnaround in global fund flows, logging a dramatic $9.98 billion net inflow in April after sharp March outflows.
-
![[Global Markets] China's Crackdown on Offshore Investment Detours Brings Reflected Benefits to Hong Kong: Scenario Review of Southbound Capital Influx into Hang Seng Index](https://daily-stock.kr/stdaily/uploads/202606/gen_6a25c0083d1543.12953496.png)
[Global Markets] China's Crackdown on Offshore Investment Detours Brings Reflected Benefits to Hong Kong: Scenario Review of Southbound Capital Influx into Hang Seng Index
China's strict crackdown on mainland investors' offshore detours is driving a massive influx of Southbound capital into the underpriced Hong Kong Hang Seng Index, creating solid downside support despite macro uncertainties.
-
Alteogen (196170) Enters Era of Scale Milestone Revenues, First Year of Earnings Leap Proven by Royalty Inflows
Alteogen (196170) is set to enter a massive milestone inflow phase driven by its SC platform technology, with billions in cash expected from Keytruda SC sales and new licensing deals amid resolved patent risks.
-
![[KOSPI Story] Entering the Quarterly Ex-Dividend Season: Financial Investment Program Arbitrage's 'U-Turn' Supply-Demand Patterns and Post-Reform Volatility Analysis](https://daily-stock.kr/stdaily/uploads/202606/gen_6a251791f0d7c5.20248024.png)
[KOSPI Story] Entering the Quarterly Ex-Dividend Season: Financial Investment Program Arbitrage's 'U-Turn' Supply-Demand Patterns and Post-Reform Volatility Analysis
KOSPI supply-demand trends and market impacts following dividend system reforms. Structural changes appear ahead of the June 2026 semi-annual and Q2 ex-dividend season, reducing traditional sharp market volatility.